Related Experiment Video
Updated: Jul 16, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Christoph R Müller1, Erik B Paulsen, Paul Noordhuis
1Department of Tumour Biology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway.
Abstract:
The MDM2-antagonist Nutlin 3A can efficiently induce apoptosis in osteosarcoma cell lines with amplified MDM2. However, Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent. The well- and de-differentiated liposarcomas have complex marker chromosomes, consistently including multiple copies of the MDM2 locus. Since amplification seems to be a primary aberration in these tumors, whereas amplification in osteosarcoma generally is a progression marker, the underlying biological mechanisms may be different. We have therefore investigated the molecular response to Nutlin treatment in several liposarcoma cell lines with such markers, as well as a panel of other sarcoma cell lines. We report that Nutlin efficiently stabilized p53 and induced downstream p53 dependent transcription and apoptosis in liposarcoma cells with amplified MDM2 in vitro. Some effect of Nutlin was also observed on cell lines without amplified MDM2 but with wt TP53, but no apoptosis was induced. The MDM4 protein, reported to interfere with the reactivation of p53, was undetectable in cells with amplified MDM2. Thus, Nutlin represents a promising new therapeutic principle for the treatment of an increasing group of sarcomas.
Insights
MDM2-antagonist Nutlin 3A induces apoptosis in liposarcoma cells with amplified MDM2. This therapy shows promise for various sarcoma types, stabilizing p53 and promoting cell death.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- MDM2-antagonist Nutlin 3A effectively induces apoptosis in osteosarcoma cell lines with MDM2 amplification.
- Liposarcomas frequently exhibit MDM2 locus amplification, suggesting potential therapeutic vulnerability.
- Understanding the molecular response to Nutlin in diverse sarcoma types is crucial for treatment development.
Purpose of the Study:
- To investigate the molecular response to Nutlin 3A treatment in liposarcoma cell lines with amplified MDM2.
- To evaluate the efficacy of Nutlin 3A in various sarcoma cell lines, including those without MDM2 amplification.
- To explore the role of MDM4 in the context of Nutlin 3A treatment and p53 reactivation.
Main Methods:
- Treatment of liposarcoma and other sarcoma cell lines with Nutlin 3A.
- Assessment of p53 stabilization and downstream transcriptional activity.
- Analysis of apoptosis induction.
- Detection of MDM4 protein levels.
Main Results:
- Nutlin 3A efficiently stabilized p53 and induced apoptosis in liposarcoma cells with amplified MDM2.
- Nutlin 3A showed some effect on cell lines with wild-type TP53 but without MDM2 amplification, though no apoptosis was observed.
- MDM4 protein was undetectable in liposarcoma cells with amplified MDM2.
Conclusions:
- Nutlin 3A is a promising therapeutic agent for sarcomas with amplified MDM2, particularly liposarcomas.
- The absence of MDM4 in MDM2-amplified cells may facilitate Nutlin 3A's efficacy.
- Nutlin 3A represents a potential new therapeutic strategy for a growing number of sarcoma patients.
More Related Videos
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
